Leqembi & Kisunla: The Breakthrough Alzheimer’s Treatments You Need to Know скачать в хорошем качестве

Leqembi & Kisunla: The Breakthrough Alzheimer’s Treatments You Need to Know

Leqembi & Kisunla: The Breakthrough Alzheimer’s Treatments You Need to Know Alzheimer’s disease is a progressive brain disorder that leads to memory loss, cognitive decline, and personality changes. Until recently, treatments could only manage symptoms. However, two FDA-approved drugs—Leqembi (lecanemab) and Kisunla (donanemab)—offer new hope by targeting the underlying causes of the disease. How Alzheimer’s Affects the Brain Alzheimer’s is driven by the accumulation of toxic proteins, leading to neuron damage and brain shrinkage. Two key culprits are: Amyloid plaques – Clumps of amyloid-beta protein that disrupt communication between brain cells. Tau tangles – Twisted proteins that block nutrient transport, causing neuron death. How Leqembi (Lecanemab) Works Leqembi is a monoclonal antibody that targets amyloid plaques, helping to clear them from the brain and slow cognitive decline. ✔️ Slows disease progression by 27% in early-stage patients. ✔️ Helps maintain memory and problem-solving skills longer. ✔️ Given biweekly through IV infusion. 💡 Side Effects: Potential brain swelling or bleeding (ARIA), headache, and dizziness. How Kisunla (Donanemab) Works Kisunla also targets amyloid plaques but focuses on modified forms that are harder to remove. ✔️ Slows disease progression by 35% in early-stage patients. ✔️ Improves daily function and reduces brain inflammation. ✔️ Administered monthly via IV infusion. 💡 Side Effects: Similar to Leqembi, including ARIA and mild flu-like symptoms. Who Can Benefit? These treatments are approved for early-stage Alzheimer’s patients with confirmed amyloid buildup. They are not recommended for late-stage patients or those with severe cognitive impairment. Challenges in Accessing Treatment High Cost Strict Eligibility: Only early-stage patients qualify. Insurance Barriers: Medicare coverage varies. The Future of Alzheimer’s Research Scientists are exploring gene therapy, early biomarker detection, and potential vaccines to prevent Alzheimer’s before symptoms appear. Final Thoughts Leqembi and Kisunla mark a major advancement in Alzheimer’s treatment, offering hope for slowing disease progression. If you or a loved one is experiencing early signs of Alzheimer’s, talk to a doctor about biomarker testing to determine eligibility for these treatments. 💡 Stay informed on the latest Alzheimer’s research! Like, share, and subscribe for updates.